Indivior Pharmaceuticals (INDV) Accounts Payables (2021 - 2026)

Indivior Pharmaceuticals' Accounts Payables history runs 6 years deep, the most recent figure standing at $178.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 2.73% year-over-year to $178.0 million in Q1 2026; TTM through Mar 2026 was $178.0 million, a 2.73% decrease from a year earlier, with the FY2025 full-year figure at $250.0 million, up 15.74% from the prior year.
• Accounts Payables fell to $178.0 million in Q1 2026 per INDV's latest filing, from $250.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $617.0 million in Q4 2022 and bottomed at $178.0 million in Q1 2026.
• The 5-year median for Accounts Payables is $205.5 million (2025), against an average of $256.2 million.
• Across the five-year window, Accounts Payables sank 68.4% in 2023 and grew 15.74% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $617.0 million in 2022, then sank by 68.4% to $195.0 million in 2023, then rose by 10.77% to $216.0 million in 2024, then gained by 15.74% to $250.0 million in 2025, then declined by 28.8% to $178.0 million in 2026.
• Per Business Quant, the three latest INDV Accounts Payables figures stand at $178.0 million (Q1 2026), $250.0 million (Q4 2025), and $215.0 million (Q3 2025).